Exelixis, Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 29, 2023 (presented for convenience as year ended December 31, 2023), compared with FY2022. Although the request metadata says “2022 Q4,” this filing is the company’s FY2023 annual report, not a 2022 quarterly filing. Figures below are in U.S. dollars.
Business context
Exelixis is an oncology company whose revenue is primarily driven by cabozantinib products CABOMETYX and COMETRIQ. CABOMETYX is marketed in the U.S. by Exelixis and internationally through Ipsen and Takeda. The company also has collaboration revenue from COTELLIC and other arrangements. Its development priorities include zanzalintinib, XB002 and XL309, alongside additional small-molecule and biotherapeutic programs.
Financial performance and liquidity
| Metric | FY2023 | FY2022 | Change |
|---|---|---|---|
| Total revenue | $1,830.2 million | $1,611.1 million | +14% |
| Net product revenue | $1,628.9 million | $1,401.2 million | +16% |
| Operating income | $170.9 million | $201.5 million | -15% |
| Net income | $207.8 million | $182.3 million | +14% |
| Diluted EPS | $0.65 | $0.56 | +$0.09 |
| Operating cash flow | $333.3 million | $362.6 million | -$29.3 million |
| Cash, cash equivalents and investments | $1,724.0 million | $2,066.7 million | -$342.7 million |
| Working capital | $923.7 million | $1,294.4 million | -$370.7 million |
- CABOMETYX revenue was $1,614.9 million, up 17%; COMETRIQ revenue was $13.9 million, down 45%. Management attributed CABOMETYX growth to higher unit sales and a higher average net selling price.
- License revenue rose 10% to $178.6 million, while collaboration services revenue fell 52% to $22.7 million, principally reflecting lower development cost reimbursements. Total collaboration revenue was $201.3 million, down from $209.8 million.
- Research and development expense increased 17% to $1,044.1 million; selling, general and administrative expense increased 18% to $542.7 million. Total operating expenses rose 18% to $1,659.3 million.
- Gross margin was reported at 96%. Operating margin was approximately 9.3% of revenue in FY2023 versus 12.5% in FY2022; net margin was approximately 11.3% versus 11.3%.
- Net income increased despite lower operating income, supported by interest income of $86.5 million, up from $33.1 million, primarily due to higher interest rates. The effective tax rate was 19.3%, versus 22.2%.
- Cash flow from investing activities was an outflow of $27.0 million; financing activities used $546.1 million, mainly for $550.4 million of share repurchases. The company held $262.994 million in cash and cash equivalents and $1,461.025 million in short- and long-term investments.
- No borrowings or funded debt are shown on the balance sheet. Reported liabilities included $215.7 million of operating lease liabilities. The company said available liquidity and expected operating receipts should fund operations for at least 12 months and thereafter for the foreseeable future.
Material changes and notable items
- Net product revenue growth was offset in operating income by higher R&D and SG&A costs. Exelixis recorded an $80 million upfront license payment for XL309 in R&D expense; acquired in-process R&D technology was $128.5 million in the cash-flow reconciliation.
- Exelixis repurchased 26.2 million shares for $550 million in 2023. In January 2024, the board authorized a further repurchase program of up to $450 million by year-end 2024.
- In January 2024, the company announced a restructuring that reduces headcount by approximately 175 employees, or 13%, and includes reducing real estate commitments and terminating certain licensing partnerships. The filing says the accounting impact was still being evaluated.
- FY2023 ended with 302.8 million shares outstanding, compared with 324.0 million a year earlier. The company reported no cash dividends and said it did not plan to pay them in the foreseeable future.
Outlook, clinical progress and risks
- Management projected FY2024 net product revenue may increase, while license revenue may remain flat and collaboration services revenue may decrease. It projected R&D and SG&A expenses may decrease following the restructuring, with higher clinical and manufacturing costs partly offsetting savings. No numeric revenue or earnings guidance was provided.
- Management estimated the FY2024 effective tax rate at 20%–22%. FY2024 is a 53-week year, which may modestly increase revenue and expenses compared with FY2023.
- CONTACT-02 met its progression-free survival endpoint for cabozantinib plus atezolizumab in metastatic castration-resistant prostate cancer; overall-survival data were immature and not statistically significant at interim analysis. Further OS analysis was anticipated in 2024.
- The CABINET phase 3 trial showed significant progression-free survival results for cabozantinib in pancreatic and extra-pancreatic neuroendocrine tumors. The company was discussing a potential FDA submission. COSMIC-313 met its PFS endpoint, but interim OS analyses had not crossed the significance threshold.
- Two phase 3 trials involving cabozantinib plus atezolizumab, CONTACT-01 and CONTACT-03, did not meet their primary endpoints. These results temper expectations for combination studies.
- Zanzalintinib was being evaluated in three pivotal or phase 2/3 trials, with additional studies underway. Pipeline outcomes remain uncertain; all candidates require further clinical and regulatory success.
- Key business risks include reliance on CABOMETYX, pricing and reimbursement pressure, competition, dependence on commercial partners outside the U.S., clinical-trial and regulatory uncertainty, third-party manufacturing reliance, and potential generic entry. Teva’s settlement permits U.S. generic CABOMETYX sales beginning January 1, 2031, if approved and subject to agreement terms. MSN litigation remained pending, and Cipla litigation was stayed.
- The company disclosed a 340B Program Integrity Initiative challenged by covered entities; no administrative dispute resolution proceedings had commenced as of the report date, and potential liability was unclear. It also cited uncertainty around drug-pricing reforms, including the Inflation Reduction Act.
Important facts for investors to verify
- Track CABOMETYX prescription demand, pricing, payer discounts and rebates, and international royalties; discounts and allowances rose 17% in FY2023.
- Review FY2024 results against management’s qualitative outlook and assess whether restructuring savings offset clinical-development and manufacturing spending.
- Follow the MSN II judgment, Cipla litigation and the implications of the Teva 2031 license date for generic competition.
- Monitor OS results and regulatory discussions for CONTACT-02, COSMIC-313 and CABINET, as well as pivotal zanzalintinib trial progress.
- Assess the use of cash for the new $450 million repurchase authorization relative to pipeline investment and liquidity needs.
- Consider the audit context: the financial statements received an unqualified audit opinion, and the auditor identified product-sales revenue recognition and customer channel inventory as a critical audit matter.